Biotech Analyst Agrawal, along with KOL Dr. Pierre Gholam, Medical Director of Liver Center of Excellence, University Hospitals of Cleveland, discuss Fazirsiran SEQUOIA data in AATD (Alpha-1 Antitrypsin Deficiency) and review NASH (Nonalcoholic Steatohepatitis) drugs on an Analyst/Industry conference call to be held on January 20 at 12 pm. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARWR:
- Cantor Fitzgerald biotech analyst to hold analyst/industry conference call
- Arrowhead price target lowered to $60 from $82 at Chardan
- Arrowhead price target lowered to $55 from $64 at Piper Sandler
- Takeda Pharmaceutical, Arrowhead announce topline results from SEQUOIA study
- Arrowhead announces $25M milestone payment from Amgen